0000950170-24-073772.txt : 20240614 0000950170-24-073772.hdr.sgml : 20240614 20240614170008 ACCESSION NUMBER: 0000950170-24-073772 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240613 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gros David-Alexandre C CENTRAL INDEX KEY: 0001644489 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 241045727 MAIL ADDRESS: STREET 1: 220 MARLBOROUGH STREET STREET 2: #6 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eledon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19800 MACARTHUR BLVD. STREET 2: SUITE 250 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19800 MACARTHUR BLVD. STREET 2: SUITE 250 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Novus Therapeutics, Inc. DATE OF NAME CHANGE: 20170511 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 4 1 ownership.xml 4 X0508 4 2024-06-13 0001404281 Eledon Pharmaceuticals, Inc. ELDN 0001644489 Gros David-Alexandre C C/O ELEDON PHARMACEUTICALS, INC. 19800 MACARTHUR BLVD STE. 250 IRVINE CA 92612 true true false false Chief Executive Officer false Stock Option (right to buy) 2.30 2024-06-13 4 A false 517454 0 A 2033-05-01 Common Stock 517454 517454 D This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. /s/ Paul Little, as attorney-in-fact for David Alexandre C. Gros, M.D. 2024-06-14